说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 词典 -> 前列环素E1脂微球制剂
1)  Lipo-PGE 1
前列环素E1脂微球制剂
1.
the therapy group was administrated with 10μg Lipo-PGE 1 every day by intravenous injection for 15 days, the control group was treated with 30 mL Fufangdanshen a day by the same means.
目的 观察前列环素E1脂微球制剂 (Lipo -PGE1)治疗急性脑梗死的临床疗效和不良反应。
2)  Lipo-prostaglandin E1
前列腺素E1脂微球载体制剂
1.
Objective To observe efficacy and safety of Lipo-prostaglandin E1(Lipo-PGE1)for the treatment of severe hepatitis.
目的观察前列腺素E1脂微球载体制剂(Lipo-PGE1)治疗重型肝炎的疗效及安全性。
2.
Changes of MELD score in patients with chronic severe hepatitis treated by Lipo-prostaglandin E1;
[目的]应用终末期肝病模型(MELD评分)评价前列腺素E1脂微球载体制剂(Lipo PGE1)对慢性重型肝炎的治疗作用。
3)  Lipo PGE 1
前列腺素E1脂微球载体制剂
1.
OBJECTIVE:To investigate the therapeutic effect of Lipo-prostaglandin E 1 (Lipo PGE 1 )on chronic severe type B hepatitis by MELD(Model for end-stage live disease)prognosis analysis.
目的:应用终末期肝病模型(MELD)预后分析研究前列腺素E1脂微球载体制剂(LipoPGE1)对慢性乙型重型肝炎的治疗作用。
2.
OBJECTIVE To observe the clinical effect of the Lipo PGE 1 in 60 patients with chronic severe hepatitis.
目的 探讨前列腺素E1脂微球载体制剂 (LipoPGE1)治疗慢性重型肝炎 6 0例临床疗效观察。
3.
Objective To study the efficacy and tolerability of Lipo PGE 1 in treatment of diabetic cystopathy.
目的 研究前列腺素E1脂微球载体制剂 (LipoPGE1,凯时 )治疗糖尿病膀胱病的临床疗效及其不良反应。
4)  Lipo-PGE1
前列腺素E1脂微球载体制剂
1.
Effects of Lipo-PGE1 on the Expression of CTGF in Kidney of Rats with Adriamyc in Nephropathy;
前列腺素E1脂微球载体制剂对多柔比星肾病大鼠结缔组织生长因子表达的影响
2.
Objective: To study the effects of Lipo-PGE1 and dexamethasone on experimental focal segmental glomerulosclerosis in rats.
目的:探讨前列腺素E1脂微球载体制剂(L ipo-PGE1),地塞米松对局灶节段性肾小球硬化模型大鼠的影响。
3.
Observation of the effect of Lipo-PGE1 on mass ascites resulting from cirrhosis of liver;
目的 观察前列腺素E1脂微球载体制剂 (Lipo PGE1)治疗肝硬化大量腹水的疗效。
5)  LipoPGE1
脂微球前列腺素E1
1.
Compaison Study of Endothelin (ET) and Nitric Oxide (NO) after Applying LipoPGE1 and Danshen on Type 2 Diabetics;
脂微球前列腺素E1与丹参对2型糖尿病患者NO、ET的对比研究
6)  liposomal prostaglandin E1(Lipo-PGE1)
脂微球载体前列腺素E1
1.
Objective The aim of the study is to discuss the validity and security of direct percutaneous transcoronary angioplasty combined with liposomal prostaglandin E1(Lipo-PGE1) for treating elderly (≥70岁)acute myocardial infarction (AMI) .
目的探讨直接经皮冠状动脉成形术(PTCA)联合脂微球载体前列腺素E1(Lipo-PGE1)治疗老年(≥70岁)急性心肌梗死的有效性和安全性。
补充资料:可降解淀粉微球和生物降解白蛋白微球阻滞法


可降解淀粉微球和生物降解白蛋白微球阻滞法


介入放射学技术。介入性局部化疗之前,把二者注入靶动脉,可暂时减少动脉血流,再行化疗药物灌注,以减少血液冲刷,保持局部化疗药物浓度的技术。与其他中期和长期栓塞微球不同,DSM和BAM仅造成数十分钟的血流量减少,待其被降解后血流可恢复至以前水平。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条